A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.

Int J Clin Oncol · 2018 · PMC5951896 · PMID 29435872

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Ultimately, the nCRT in this trial’s population provided a highly significant 34% reduction of the risk of death, as well as a significant 42% reduction of the risk of relapse [ 11 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.